Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

We reached out to Novo Nordisk, the company that manufactures ... including doctors, pharmacies, and other experts in the field, and just like Ann, we heard mixed things about why there could ...

Type 1 Diabetes Market is expected to reach USD 24.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. BURLINGAME, CA, UNITED STATES, October 27, 2024 ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

The article included a statement made by a Novo Nordisk global senior leader that the regulator said “promoted a prescription only medicine to the public in a way that was misleading.” The statement ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical ... and “inappropriate sponsorship arrangements.” The Prescription Medicines Code of Practice Authority (PMCPA), the ...